Literature DB >> 23990342

The Surviving Sepsis Campaign's Revised Sepsis Bundles.

Amisha V Barochia1, Xizhong Cui, Peter Q Eichacker.   

Abstract

The Surviving Sepsis Campaign (SSC) sepsis care bundles have recently been revised. The original 6-h resuscitation bundle which included rapid antibiotic administration and hemodynamic support with early goal-directed therapy (EGDT) has been divided into two bundles; one including antibiotic and fluid support to be completed within 3 h, and the other including vasopressor support and measures of central venous pressure and oxygen saturation to be completed within 6 h. The original 24-h management bundle targeting glucose control, administration of corticosteroids and recombinant human activated protein C (rhAPC), and limitation of plateau airway pressures during mechanical ventilation is no longer recommended. Past and recent reports by the SSC and others have suggested that compliance with the original bundles was low and their impact unclear. Examination of the revised bundles in the context of issues and questions arising with the original ones suggest that while compliance with new 3-h bundle will be high, compliance with the 6-h bundle will continue to be low.

Entities:  

Year:  2013        PMID: 23990342      PMCID: PMC3864669          DOI: 10.1007/s11908-013-0351-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  35 in total

Review 1.  The Surviving Sepsis Campaign: a history and a perspective.

Authors:  John C Marshall; R Phillip Dellinger; Mitchell Levy
Journal:  Surg Infect (Larchmt)       Date:  2010-06       Impact factor: 2.150

2.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.

Authors:  Peter Q Eichacker; Charles Natanson; Robert L Danner
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

3.  Prospective external validation of the clinical effectiveness of an emergency department-based early goal-directed therapy protocol for severe sepsis and septic shock.

Authors:  Alan E Jones; Anne Focht; James M Horton; Jeffrey A Kline
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

4.  The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.

Authors:  Mitchell M Levy; R Phillip Dellinger; Sean R Townsend; Walter T Linde-Zwirble; John C Marshall; Julian Bion; Christa Schorr; Antonio Artigas; Graham Ramsay; Richard Beale; Margaret M Parker; Herwig Gerlach; Konrad Reinhart; Eliezer Silva; Maurene Harvey; Susan Regan; Derek C Angus
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

5.  The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. An assessment by the Australian and New Zealand intensive care society.

Authors:  P Hicks; D J Cooper; S Webb; J Myburgh; I Seppelt; S Peake; C Joyce; D Stephens; A Turner; C French; G Hart; I Jenkins; A Burrell
Journal:  Anaesth Intensive Care       Date:  2008-03       Impact factor: 1.669

6.  Sepsis bundles and compliance with clinical guidelines.

Authors:  Lisa Stoneking; Kurt Denninghoff; Lawrence Deluca; Samuel M Keim; Benson Munger
Journal:  J Intensive Care Med       Date:  2011 May-Jun       Impact factor: 3.510

7.  [The effect of early goal-directed therapy on treatment of critical patients with severe sepsis/septic shock: a multi-center, prospective, randomized, controlled study].

Authors: 
Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue       Date:  2010-06

8.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

9.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

Review 10.  Bench-to-bedside review: the initial hemodynamic resuscitation of the septic patient according to Surviving Sepsis Campaign guidelines--does one size fit all?

Authors:  Azriel Perel
Journal:  Crit Care       Date:  2008-09-03       Impact factor: 9.097

View more
  4 in total

1.  Prognostic value of CD4(+)CD25(+) Tregs as a valuable biomarker for patients with sepsis in ICU.

Authors:  Kun Chen; Qiu-Xiang Zhou; Hong-Wei Shan; Wen-Fang Li; Zhao-Fen Lin
Journal:  World J Emerg Med       Date:  2015

2.  The duration of hypotension determines the evolution of bacteremia-induced acute kidney injury in the intensive care unit.

Authors:  Karin Janssen van Doorn; Walter Verbrugghe; Kristien Wouters; Hilde Jansens; Philippe G Jorens
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

3.  Impact of appropriate antimicrobial therapy for patients with severe sepsis and septic shock--a quality improvement study.

Authors:  Paula K O Yokota; Alexandre R Marra; Marines D V Martino; Elivane S Victor; Marcelino S Durão; Michael B Edmond; Oscar F P dos Santos
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

4.  Adherence to the SEP-1 Sepsis Bundle in Hospital-Onset v. Community-Onset Sepsis: a Multicenter Retrospective Cohort Study.

Authors:  Jonathan D Baghdadi; Mitchell D Wong; Daniel Z Uslan; Douglas Bell; William E Cunningham; Jack Needleman; Russell Kerbel; Robert Brook
Journal:  J Gen Intern Med       Date:  2020-02-10       Impact factor: 6.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.